Therapeutic Drug Monitoring Market by Product & Class of Drug - 2020 JULY 2018

Therapeutic Drug Monitoring Market by Product (Consumables, Equipment), Technology
(Immunoassays, Proteomic Technologies), Class of Drug (Antiepileptics, Antibiotics,
Immunosuppressants), End User (Hospital Labs, Private Labs) - Global Forecast to 2020
The Market Research on Therapeutic Drug Monitoring, By Considering useful aspects like;
Application, End Users- Global Future Forecast till 2020, published by MarketsandMarkets™,
the report studies the global Therapeutic Drug Monitoring market over the forecast period to
2020. The market is projected to reach USD 2.55 Billion by 2020 at a CAGR of 7.4%.
The study estimates the Therapeutic Drug Monitoring market size for 2018 and projects its
demand till 2020. In the primary research process, various sources from both demand side and
supply side were interviewed to obtain qualitative and quantitative information for the report.
Primary sources from the demand side include research scientists, Therapeutic Drug Monitoring
specialists, laboratory technicians, and R&D professionals of pharmaceutical and biotechnology
companies and academic research institutes.
The market is broadly segmented by product, technology, class of drug, end user, and region.
On the basis of product, the Therapeutic Drug Monitoring market is segmented into
consumables and equipment. The equipment market is further segmented into immunoassay
analyzers, proteomic equipment, and other equipment. The consumables segment is expected
to account for nearly two-thirds of the global market. The immunoassay analyzers segment is
expected to be the fastest-growing segment in its equipment market. Comparatively low costs
of immunoassay analyzers and their ease of use are the primary factors driving the market
growth in this segment.
On the basis of technology, the therapeutic drug monitoring market is categorized into three
segments namely, immunoassays, proteomic technologies and others. The immunoassays
segment is expected to account for the largest share of its technology market in 2015. Factors
such as relatively simple tests and requirement of minimal training to handle the immunoassay
analyzers will drive the growth of this segment.
On the basis of class of drug, the market is segmented into antiepileptics, antibiotics,
immunosuppressants, antiarrhythmic drugs, bronchodilators, psychoactive drugs, and other
classes. The antiepileptics segment is estimated to account for the largest share in 2015. By end
user, the market is divided into hospital labs, commercial/private labs, and other end users. The
hospital labs segment is estimated to account for the largest share in 2015.
1